Koers Threshold Pharmaceuticals, Inc. Nasdaq
Aandelen
US8858072064
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 12,7 mln. 11,7 mln. | Omzet 2025 * | 1,37 mln. 1,26 mln. | Marktkapitalisatie | 8,95 mln. 8,25 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -22 mln. -20,27 mln. | Nettowinst (verlies) 2025 * | -34 mln. -31,32 mln. | EV/omzet 2024 * | 0,7 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 6,55 x |
K/w-verhouding 2024 * |
-0,42
x | K/w-verhouding 2025 * |
-0,35
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,04% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Jason Kim
PSD | President | 49 | 01-01-10 |
Kristen Quigley
COO | Chief Operating Officer | 53 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric Poma
CEO | Chief Executive Officer | 52 | 01-01-00 |
Harold Selick
CHM | Chairman | 69 | 01-08-17 |
David Hoffmann
BRD | Director/Board Member | 79 | 01-08-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,63% | 115 mld. | |
+13,17% | 107 mld. | |
-12,76% | 22,31 mld. | |
-3,99% | 21,6 mld. | |
-7,19% | 18,23 mld. | |
-39,93% | 17,62 mld. | |
+6,67% | 14,26 mld. | |
+33,90% | 12,37 mld. | |
-28,60% | 8,28 mld. |